DS
TXG icon

DRW Securities’s 10x Genomics TXG Stock Holding History

DRW Securities’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,545
Closed -$174K – 1712
2025
Q3 		$174K Buy
+14,545
New +$190K ﹤0.01% 1109

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities's TXG Position: Q4 2025 in Review

DRW Securities sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 14,545 shares — an estimated $174K sold.

DRW Securities first reported a position in TXG in Q3 2025 and held it in 1 quarter. The position peaked at $174K in Q3 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • DRW Securities reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • DRW Securities sold 14,545 10x Genomics shares in Q4 2025, an estimated $174K.
  • DRW Securities first reported a position in 10x Genomics in Q3 2025 and held it in 1 quarter.
  • DRW Securities's 10x Genomics position peaked at $174K in Q3 2025.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.